SLU-PP-332vsTesamorelin

SLU-PP-332 is a small molecule agonist of estrogen-related receptor alpha (ERRα), one of three orphan nuclear receptors in the ERR family. Despite its name, ERRα does not bind estrogen — it was named for its structural similarity to estrogen receptors. ERRα is constitutively active and functions as a master transcription factor for genes controlling mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation, particularly in metabolically active tissues like skeletal muscle, heart, and brown adipose tissue.

SLU-PP-332 enhances ERRα transcriptional activity by stabilizing its active conformation and promoting coactivator recruitment (particularly PGC-1α, which is both an ERRα target gene and an ERRα coactivator, creating a positive feed-forward loop). Activated ERRα binds to ERR response elements (ERREs) in the promoter regions of hundreds of metabolic genes, upregulating the entire oxidative metabolism gene program: mitochondrial electron transport chain subunits, fatty acid oxidation enzymes, TCA cycle enzymes, and mitochondrial transcription and replication factors.

The most striking effect in preclinical studies is the transformation of skeletal muscle fiber type composition. SLU-PP-332 treatment increases the proportion of slow-twitch (type I) and oxidative fast-twitch (type IIA) fibers while decreasing glycolytic fast-twitch (type IIB/IIX) fibers. Type I fibers are rich in mitochondria, capillaries, and myoglobin — they are the fibers that endurance athletes develop through years of training. By pharmacologically shifting this fiber type ratio, SLU-PP-332 produces endurance capacity gains similar to what would require months of aerobic training. In mouse studies published in 2023, treated animals ran significantly longer and farther on treadmill tests. This ERRα-mediated mechanism is distinct from and potentially complementary to AMPK-based exercise mimetics like AICAR, as it targets a different node in the mitochondrial biogenesis regulatory network.

Tesamorelin is a synthetic GHRH analogue consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This lipophilic modification enhances receptor binding affinity and provides modest resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, improving its pharmacokinetic profile compared to native GHRH.

Like other GHRH analogues, tesamorelin activates the GHRH receptor on pituitary somatotrophs via the Gs/cAMP/PKA pathway, stimulating endogenous GH synthesis and pulsatile secretion. The resulting increase in circulating GH and IGF-1 produces its primary therapeutic effect: targeted reduction of visceral adipose tissue (VAT). GH-mediated lipolysis is particularly active in visceral fat depots because these adipocytes have the highest density of GH receptors and are most responsive to GH-stimulated hormone-sensitive lipase activation.

The specificity of tesamorelin's effect on visceral rather than subcutaneous fat has been well-documented in clinical trials. Visceral adipose tissue is metabolically distinct — it drains directly into the portal circulation and contributes disproportionately to hepatic insulin resistance, inflammatory cytokine production, and cardiovascular risk. By selectively reducing this depot, tesamorelin improves the cardiometabolic profile beyond what would be expected from total fat loss alone. Clinical trials also showed improvements in hepatic steatosis (fatty liver) markers, triglyceride levels, and trunk fat distribution. It remains the only GHRH analogue with active FDA approval, specifically for HIV-associated lipodystrophy, where visceral fat accumulation is a common and distressing side effect of antiretroviral therapy.